Iovance Biotherapeutics financial performance and stock rise

Iovance Biotherapeutics experienced significant financial growth and stock market momentum in mid-2026. The company reported second-quarter revenue of approximately $99.3 million, representing a 66% increase from the previous year and exceeding analyst expectations. This growth was largely attributed to $91 million in U.S. sales of its cell therapy, Amtagvi, for advanced melanoma.

Following these results, the company’s stock saw an initial surge of over 30%. By mid-August, the shares had rallied more than 130% year-to-date, approaching 52-week highs. While technical indicators showed a strong bullish trend with prices remaining above key moving averages, analysis also noted the stock might be in overbought territory due to a high Relative Strength Index.

By August 15, 2026, the stock reached a 52-week high, closing at $6.98. This rally followed record revenue for Amtagvi and improved gross margins in the second quarter. Despite the upward momentum, technical indicators such as the RSI continued to suggest overbought conditions.